Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA bank aims to unlock why childhood cancer survivors face heart and organ risks

NCT ID NCT02666625

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are building a bank of blood and saliva samples from adults who were treated for cancer as children. The goal is to study genetic factors that may affect the risk of long-term side effects from childhood cancer treatment, such as heart, brain, lung, bone, and kidney problems. By linking genetic data with health outcomes, the study may help doctors better understand and eventually prevent these late effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers identify genetic variants linked to heart, brain, lung, bone, or kidney damage after childhood cancer treatment, doctors could one day use that information to tailor treatment and prevent these late effects.
What could go wrong
This is an observational biobank study, so it cannot prove cause and effect. Genetic associations may turn out to be weak or not replicable, and any prevention strategies would still need separate testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2013

Expected to finish

Dec 2036

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated for a paediatric malignancies before the year 2000 having survived two years after treatment of solid tumor diagnosed before 18 years old

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients treated for a first cancer in childhood * Adult patients * Signed informed consent * Patient insured or enjoying a social security scheme Exclusion Criteria: * Minor patients * Under legal protection measure patients * Refusal of consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Paediatric malignancies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Paediatric malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69008, France

  • Gustave Roussy Cancer Campus Grand Paris

    RECRUITING

    Villejuif, Val de Marne, 94805, France

  • Institut Curie

    RECRUITING

    Paris, 75005, France